Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorTanta University

About this trial

Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.

Eligibility criteria

Qualifiers

Age more than 18 years old.

Gender: Males and Females

Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.

Blood amylase and lipase levels before ERCP are within the normal limits

Disqualifiers

Uncontrolled diabetes mellitus (DM)

Severe bleeding tendency

Impaired renal function (serum creatinine > 2 mg/dL), (creatinine clearance <30 ml/min)

Patients with severe heart disease.

Trial design

Treatments tested in this trial

  • Duloxetine
  • Placebo capsule

Treatment groups

44 Participants
are divided into 2 treatment groups

Sponsors and collaborators